David Younger says his company's model training showed that solving truly hard protein design problems will require much more data than the field expects. He also warns public binding and affinity data are often not interoperable, lack proper controls, and lack annotations, making them hard to reuse.
Younger says the Protein Data Bank today holds about 10,000 antibody-antigen structures and adds roughly 1,000 yearly. Their internal scaling work suggests good generalizable de novo design models may need hundreds of thousands to millions of structures, so waiting on PDB growth is far too slow.
Younger notes the PDB shows how proteins physically interact but not how strongly, and it has almost no examples of antibodies one or two mutations apart with measured affinities. Zero-shot optimization instead needs local affinity landscapes built from many single-point mutation variants across many targets.
AlphaSeq re-engineers yeast mating so surface-displayed protein interactions drive cell fusion. Younger says bulk selection and next-generation sequencing read out pairwise affinities, letting one flask measure a million interactions instead of one well measuring a single interaction, avoiding traditional one-at-a-time protein purification and characterization.
Younger says de novo designs currently achieve reasonable single-digit percent success rates only against the easiest targets and epitopes. The field's ambition is to engineer challenging epitopes and additional properties, where success rates remain very low; he argues more and better data are still needed.
Younger says model makers evaluate on unique bespoke targets, so pharma buyers cannot tell which model is best. He is working with companies on a benchmark that standardizes target difficulty and characterizes tens of thousands of designs, hoping to get true apples-to-apples comparisons with tighter error bars.
